Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial.

Int J Hematol · 2026 · PMC13319684 · PMID 41894094

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The best confirmed response showed a trend of improvement in the D-VRd group relative to the VRd group (Fig. 3 ; Supplementary Table 1).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.